1-11 of 11
Jeffrey W. Tyner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia

Rucha V. Modak, Katia G. de Oliveira Rebola, John McClatchy, Mona Mohammadhosseini, Alisa Damnernsawad, Stephen E. Kurtz, Christopher A. Eide, Guanming Wu, Ted Laderas, Tamilla Nechiporuk, Marina A. Gritsenko, Joshua R. Hansen, Chelsea Hutchinson, Sara J.C. Gosline, Paul Piehowski, Daniel Bottomly, Nicholas Short, Karin Rodland, Shannon K. McWeeney, Jeffrey W. Tyner, Anupriya Agarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2245–2259.
https://doi.org/10.1158/1078-0432.CCR-23-2654
Published: 15 May 2024
View article titled, Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Open the PDF for Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner

Tingting Liu, Vi Lam, Elana Thieme, Duanchen Sun, Xiaoguang Wang, Fei Xu, Lili Wang, Olga V. Danilova, Zheng Xia, Jeffrey W. Tyner, Stephen E. Kurtz, Alexey V. Danilov
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4910–4922.
https://doi.org/10.1158/1078-0432.CCR-21-0464
Published: 01 September 2021
View article titled, Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a <em>TP53-</em> and <em>BAX-</em>Dependent Manner
Open the PDF for Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a <em>TP53-</em> and <em>BAX-</em>Dependent Manner in another window
Includes: Supplementary data
Journal Articles

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Srividya B. Balachander, Steven W. Criscione, Kate F. Byth, Justin Cidado, Ammar Adam, Paula Lewis, Terry Macintyre, Shenghua Wen, Deborah Lawson, Kathleen Burke, Tristan Lubinski, Jeffrey W. Tyner, Stephen E. Kurtz, Shannon K. McWeeney, Jeffrey Varnes, R. Bruce Diebold, Thomas Gero, Stephanos Ioannidis, Edward J. Hennessy, William McCoull, Jamal C. Saeh, Areya Tabatabai, Omid Tavana, Nancy Su, Alwin Schuller, Mathew J. Garnett, Patricia Jaaks, Elizabeth A. Coker, Gareth P. Gregory, Andrea Newbold, Ricky W. Johnstone, Eric Gangl, Martin Wild, Michael Zinda, J. Paul Secrist, Barry R. Davies, Stephen E. Fawell, Francis D. Gibbons
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6535–6549.
https://doi.org/10.1158/1078-0432.CCR-20-0863
Published: 15 December 2020
View article titled, AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Open the PDF for AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia in another window
Includes: Supplementary data
Journal Articles

Abstract 08: Advancing precision medicine combination drug screening: A miniaturized single-cell imaging platform for evaluating immunotherapy-small molecule combination therapeutics in individuals

Thomas Jacob, Yunqi Yan, Yoko Kosaka, Sophia Jena, Stephen E. Kurtz, Andy Kaempf, Tomi Mori, Young Hwan Chang, Bill H. Chang, Uma Borate, Elie Traer, Shannon K. McWeeney, Jody Martin, Jeffrey W. Tyner, Evan F. Lind, Tania Q. Vu
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_1): 08.
https://doi.org/10.1158/1557-3265.ADVPRECMED20-08
Published: 15 June 2020
View article titled, Abstract 08: Advancing precision medicine combination drug screening: A miniaturized single-cell imaging platform for evaluating immunotherapy-small molecule combination therapeutics in individuals
Journal Articles

Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes

Stephen E. Kurtz, Beth Wilmot, Shannon McWeeney, Avanish Vellanki, Andrea Local, Khalid Benbatoul, Peter Folger, Susan Sheng, Hongying Zhang, Stephen B. Howell, William G. Rice, Brian J. Druker, Jeffrey W. Tyner
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 44.
https://doi.org/10.1158/1557-3265.HEMMAL17-44
Published: 14 December 2017
View article titled, Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes
Journal Articles

Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma

Haibo Sun, De-Chen Lin, Qi Cao, Brendan Pang, David D. Gae, Victor Kwan Min Lee, Huey Jin Lim, Ngan Doan, Jonathan W. Said, Sigal Gery, Marilynn Chow, Anand Mayakonda, Charles Forscher, Jeffrey W. Tyner, H. Phillip Koeffler
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4376–4387.
https://doi.org/10.1158/1078-0432.CCR-16-2185
Published: 01 August 2017
View article titled, Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma
Open the PDF for Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma in another window
Includes: Supplementary data
Journal Articles

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models

Deborah DeRyckere, Alisa B. Lee-Sherick, Madeline G. Huey, Amanda A. Hill, Jeffrey W. Tyner, Kristen M. Jacobsen, Lauren S. Page, Gregory G. Kirkpatrick, Fatma Eryildiz, Stephanie A. Montgomery, Weihe Zhang, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Douglas K. Graham
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (6): 1481–1492.
https://doi.org/10.1158/1078-0432.CCR-16-1330
Published: 14 March 2017
View article titled, UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
Open the PDF for UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models in another window
Includes: Supplementary data
Journal Articles

The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I

Julia E. Maxson, Samuel B. Luty, Jason D. MacManiman, Jason C. Paik, Jason Gotlib, Peter Greenberg, Swaleh Bahamadi, Samantha L. Savage, Melissa L. Abel, Christopher A. Eide, Marc M. Loriaux, Emily A. Stevens, Jeffrey W. Tyner
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 757–764.
https://doi.org/10.1158/1078-0432.CCR-14-3100
Published: 31 January 2016
View article titled, The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I
Open the PDF for The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I in another window
Includes: Supplementary data
Journal Articles

Abstract IA04: Functional genomics for discovery of pathogenic mechanisms of disease and novel therapies for hematologic malignancies

Jeffrey W. Tyner
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1_Supplement): IA04.
https://doi.org/10.1158/1557-3265.PMSCLINGEN15-IA04
Published: 03 January 2016
View article titled, Abstract IA04: Functional genomics for discovery of pathogenic mechanisms of disease and novel therapies for hematologic malignancies
Journal Articles

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Anupriya Agarwal, Ryan J. MacKenzie, Raffaella Pippa, Christopher A. Eide, Jessica Oddo, Jeffrey W. Tyner, Rosalie Sears, Michael P. Vitek, María D. Odero, Dale J. Christensen, Brian J. Druker
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (8): 2092–2103.
https://doi.org/10.1158/1078-0432.CCR-13-2575
Published: 15 April 2014
View article titled, Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Open the PDF for Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies

Kim-Hien T. Dao, Jeffrey W. Tyner
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (6): 1309–1311.
https://doi.org/10.1158/1078-0432.CCR-12-3934
Published: 14 March 2013
View article titled, Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies
Open the PDF for Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies in another window
Includes: Supplementary data